|

TROP2-CAR-NK Cells Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 2

Top Sponsors

  • M.D. Anderson Cancer Center2

Indications

  • Cancer2
  • Minimal Residual Disease1
  • Solid Tumors1
  • Colorectal Cancer1

Houston, Texas2 trials

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

MD Anderson Cancer Center

Phase 1
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.